Emre Vural
Concepts (299)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mandibular Fractures | 5 | 2013 | 8 | 1.740 |
Why?
| Surgical Flaps | 8 | 2023 | 119 | 1.680 |
Why?
| Skin Transplantation | 7 | 2010 | 43 | 1.410 |
Why?
| Head and Neck Neoplasms | 13 | 2023 | 268 | 1.390 |
Why?
| Oropharyngeal Neoplasms | 2 | 2024 | 19 | 1.350 |
Why?
| Graft Survival | 6 | 2019 | 150 | 1.160 |
Why?
| Fracture Fixation, Internal | 4 | 2013 | 40 | 1.160 |
Why?
| Free Tissue Flaps | 6 | 2023 | 59 | 1.130 |
Why?
| Rhinoplasty | 3 | 2012 | 10 | 1.040 |
Why?
| Enteral Nutrition | 2 | 2024 | 147 | 0.980 |
Why?
| Deglutition | 1 | 2024 | 42 | 0.920 |
Why?
| Deglutition Disorders | 1 | 2024 | 77 | 0.870 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2009 | 201 | 0.870 |
Why?
| Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 7 | 0.790 |
Why?
| Retrospective Studies | 26 | 2024 | 6108 | 0.770 |
Why?
| Robotics | 1 | 2021 | 43 | 0.740 |
Why?
| Skin | 6 | 2010 | 409 | 0.740 |
Why?
| Facial Paralysis | 2 | 2019 | 24 | 0.730 |
Why?
| Bone Plates | 2 | 2013 | 16 | 0.730 |
Why?
| Nasolabial Fold | 1 | 2019 | 1 | 0.680 |
Why?
| Fracture Fixation | 2 | 2012 | 16 | 0.660 |
Why?
| Neck | 5 | 2021 | 99 | 0.600 |
Why?
| Carcinoma, Squamous Cell | 6 | 2022 | 318 | 0.580 |
Why?
| Skin, Artificial | 2 | 2007 | 10 | 0.570 |
Why?
| Humans | 49 | 2024 | 49974 | 0.540 |
Why?
| Wound Healing | 4 | 2010 | 204 | 0.530 |
Why?
| Collagen | 2 | 2007 | 206 | 0.510 |
Why?
| Recurrent Laryngeal Nerve | 2 | 2021 | 13 | 0.500 |
Why?
| Neck Dissection | 4 | 2021 | 31 | 0.500 |
Why?
| Laryngeal Nerves | 2 | 2021 | 16 | 0.500 |
Why?
| Male | 29 | 2024 | 25241 | 0.480 |
Why?
| Middle Aged | 22 | 2024 | 12069 | 0.480 |
Why?
| Postoperative Complications | 7 | 2024 | 984 | 0.460 |
Why?
| Mandibular Reconstruction | 2 | 2023 | 15 | 0.450 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2010 | 56 | 0.440 |
Why?
| Laryngectomy | 3 | 2010 | 28 | 0.440 |
Why?
| Tracheotomy | 1 | 2012 | 13 | 0.430 |
Why?
| Hypopharyngeal Neoplasms | 1 | 2012 | 7 | 0.430 |
Why?
| Forehead | 1 | 2012 | 8 | 0.410 |
Why?
| Female | 27 | 2024 | 26472 | 0.410 |
Why?
| Device Removal | 1 | 2013 | 85 | 0.410 |
Why?
| Gastrostomy | 1 | 2012 | 55 | 0.410 |
Why?
| Chemoradiotherapy | 1 | 2012 | 40 | 0.410 |
Why?
| Nose | 1 | 2012 | 31 | 0.400 |
Why?
| Adult | 17 | 2024 | 13236 | 0.400 |
Why?
| Rhytidoplasty | 1 | 2011 | 6 | 0.380 |
Why?
| Laser Therapy | 2 | 2011 | 84 | 0.380 |
Why?
| Aged | 14 | 2024 | 9310 | 0.370 |
Why?
| Thyroidectomy | 2 | 2021 | 59 | 0.370 |
Why?
| Face | 1 | 2011 | 60 | 0.370 |
Why?
| Follow-Up Studies | 7 | 2023 | 2182 | 0.360 |
Why?
| Lasers | 2 | 2007 | 123 | 0.360 |
Why?
| Laryngeal Neoplasms | 2 | 2007 | 42 | 0.350 |
Why?
| Pharyngeal Diseases | 1 | 2010 | 14 | 0.350 |
Why?
| Cutaneous Fistula | 1 | 2010 | 15 | 0.350 |
Why?
| Treatment Outcome | 10 | 2021 | 5141 | 0.350 |
Why?
| Rhinophyma | 1 | 2009 | 1 | 0.340 |
Why?
| Fistula | 1 | 2010 | 24 | 0.340 |
Why?
| Hemostasis, Surgical | 1 | 2009 | 12 | 0.340 |
Why?
| Surgical Instruments | 1 | 2009 | 28 | 0.340 |
Why?
| Molar | 1 | 2009 | 2 | 0.340 |
Why?
| Biocompatible Materials | 2 | 2007 | 69 | 0.330 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 22 | 0.320 |
Why?
| Port-Wine Stain | 1 | 2008 | 14 | 0.320 |
Why?
| Quality of Life | 2 | 2012 | 836 | 0.310 |
Why?
| Tinea | 1 | 2007 | 2 | 0.300 |
Why?
| Arthrodermataceae | 1 | 2007 | 3 | 0.300 |
Why?
| Trichophyton | 1 | 2007 | 3 | 0.300 |
Why?
| Colony Count, Microbial | 1 | 2007 | 66 | 0.300 |
Why?
| Resins, Synthetic | 1 | 2007 | 3 | 0.300 |
Why?
| External Fixators | 1 | 2007 | 9 | 0.300 |
Why?
| Computer-Aided Design | 1 | 2007 | 21 | 0.290 |
Why?
| Nose Deformities, Acquired | 1 | 2007 | 2 | 0.290 |
Why?
| Mandible | 1 | 2007 | 21 | 0.290 |
Why?
| Lasers, Solid-State | 1 | 2007 | 32 | 0.290 |
Why?
| Nasal Septum | 1 | 2007 | 8 | 0.290 |
Why?
| Models, Anatomic | 1 | 2007 | 39 | 0.290 |
Why?
| Aged, 80 and over | 7 | 2022 | 3129 | 0.280 |
Why?
| Patient Care Planning | 1 | 2007 | 67 | 0.280 |
Why?
| Chi-Square Distribution | 4 | 2012 | 280 | 0.280 |
Why?
| Dermis | 1 | 2006 | 18 | 0.270 |
Why?
| Carcinoma | 3 | 2024 | 138 | 0.250 |
Why?
| Carcinoma, Merkel Cell | 2 | 2016 | 41 | 0.250 |
Why?
| Prospective Studies | 4 | 2024 | 2364 | 0.250 |
Why?
| Mandibular Condyle | 1 | 2004 | 5 | 0.250 |
Why?
| Reoperation | 2 | 2021 | 454 | 0.240 |
Why?
| Salivary Gland Neoplasms | 1 | 2024 | 7 | 0.240 |
Why?
| Fluoroscopy | 1 | 2024 | 43 | 0.240 |
Why?
| Video Recording | 1 | 2024 | 79 | 0.230 |
Why?
| Head | 3 | 2021 | 73 | 0.230 |
Why?
| Operative Time | 1 | 2023 | 73 | 0.220 |
Why?
| Scapula | 1 | 2023 | 19 | 0.220 |
Why?
| Surgery, Computer-Assisted | 1 | 2023 | 55 | 0.220 |
Why?
| Length of Stay | 2 | 2023 | 619 | 0.210 |
Why?
| Tramadol | 1 | 2022 | 30 | 0.210 |
Why?
| Intraoperative Care | 1 | 2021 | 54 | 0.200 |
Why?
| Glossectomy | 1 | 2021 | 6 | 0.200 |
Why?
| Chylothorax | 1 | 2021 | 15 | 0.190 |
Why?
| Tongue | 1 | 2021 | 39 | 0.190 |
Why?
| Nuclear Proteins | 2 | 2015 | 242 | 0.190 |
Why?
| Hypotension | 1 | 2021 | 63 | 0.190 |
Why?
| Vasoconstrictor Agents | 1 | 2021 | 84 | 0.190 |
Why?
| Arteries | 1 | 2021 | 93 | 0.190 |
Why?
| Venous Thrombosis | 1 | 2021 | 90 | 0.180 |
Why?
| Morbidity | 1 | 2021 | 133 | 0.180 |
Why?
| Intraoperative Complications | 1 | 2021 | 112 | 0.180 |
Why?
| Skin Neoplasms | 2 | 2016 | 488 | 0.180 |
Why?
| Acetaminophen | 1 | 2022 | 283 | 0.170 |
Why?
| Rats, Sprague-Dawley | 3 | 2009 | 1597 | 0.170 |
Why?
| Analgesics, Opioid | 2 | 2022 | 552 | 0.170 |
Why?
| Random Allocation | 2 | 2010 | 281 | 0.160 |
Why?
| Health Status Indicators | 1 | 2019 | 83 | 0.160 |
Why?
| Recovery of Function | 2 | 2012 | 188 | 0.150 |
Why?
| Neovascularization, Physiologic | 2 | 2009 | 68 | 0.150 |
Why?
| Time Factors | 4 | 2012 | 2903 | 0.150 |
Why?
| Patient Satisfaction | 1 | 2019 | 273 | 0.150 |
Why?
| Heart Defects, Congenital | 1 | 2023 | 595 | 0.140 |
Why?
| Rats | 3 | 2009 | 3305 | 0.140 |
Why?
| Animals | 7 | 2016 | 13187 | 0.140 |
Why?
| Tomography, X-Ray Computed | 3 | 2023 | 1159 | 0.140 |
Why?
| Risk Assessment | 2 | 2012 | 1259 | 0.140 |
Why?
| Benzoxazoles | 1 | 2016 | 11 | 0.130 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2016 | 77 | 0.130 |
Why?
| Proto-Oncogene Proteins c-myb | 1 | 2015 | 8 | 0.130 |
Why?
| Comorbidity | 2 | 2019 | 615 | 0.120 |
Why?
| Cell Proliferation | 2 | 2016 | 1007 | 0.120 |
Why?
| Cohort Studies | 2 | 2024 | 1422 | 0.120 |
Why?
| Pyrimidines | 1 | 2016 | 192 | 0.120 |
Why?
| Adolescent | 4 | 2009 | 6356 | 0.120 |
Why?
| Apoptosis | 2 | 2016 | 1101 | 0.110 |
Why?
| Survival Analysis | 2 | 2012 | 653 | 0.110 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 828 | 0.110 |
Why?
| Neoplasm Recurrence, Local | 3 | 2022 | 614 | 0.110 |
Why?
| Jaw Fixation Techniques | 1 | 2012 | 1 | 0.110 |
Why?
| Cancer Care Facilities | 1 | 2012 | 20 | 0.110 |
Why?
| Multiple Trauma | 1 | 2012 | 32 | 0.100 |
Why?
| Leukoplakia, Oral | 1 | 2011 | 6 | 0.100 |
Why?
| Aminolevulinic Acid | 1 | 2011 | 8 | 0.100 |
Why?
| Cartilage | 1 | 2012 | 48 | 0.100 |
Why?
| Lasers, Dye | 1 | 2011 | 9 | 0.100 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 374 | 0.100 |
Why?
| Photosensitizing Agents | 1 | 2011 | 21 | 0.100 |
Why?
| Thyroid Gland | 2 | 2022 | 73 | 0.100 |
Why?
| Critical Pathways | 2 | 2023 | 39 | 0.100 |
Why?
| Transcription Factors | 1 | 2015 | 561 | 0.100 |
Why?
| Photochemotherapy | 1 | 2011 | 34 | 0.100 |
Why?
| Rotation | 1 | 2011 | 45 | 0.090 |
Why?
| Arkansas | 2 | 2019 | 1977 | 0.090 |
Why?
| Taxoids | 1 | 2010 | 37 | 0.090 |
Why?
| Drug Resistance, Multiple | 1 | 2010 | 23 | 0.090 |
Why?
| Pain, Postoperative | 2 | 2022 | 158 | 0.090 |
Why?
| Epigenomics | 1 | 2011 | 67 | 0.090 |
Why?
| Mice, Knockout | 2 | 2010 | 841 | 0.090 |
Why?
| Granulation Tissue | 1 | 2010 | 10 | 0.090 |
Why?
| DNA, Neoplasm | 1 | 2011 | 147 | 0.090 |
Why?
| Tissue and Organ Harvesting | 1 | 2010 | 23 | 0.090 |
Why?
| Myeloid Cells | 1 | 2010 | 38 | 0.090 |
Why?
| Pectoralis Muscles | 1 | 2010 | 6 | 0.090 |
Why?
| Probability | 1 | 2010 | 164 | 0.090 |
Why?
| Biopsy, Fine-Needle | 1 | 2010 | 103 | 0.090 |
Why?
| Neoplasm Invasiveness | 2 | 2007 | 267 | 0.090 |
Why?
| Neoplastic Stem Cells | 1 | 2011 | 103 | 0.090 |
Why?
| Microsatellite Instability | 1 | 2009 | 17 | 0.090 |
Why?
| Statistics, Nonparametric | 2 | 2007 | 194 | 0.090 |
Why?
| Esthetics | 1 | 2009 | 14 | 0.090 |
Why?
| Ultrasonography, Interventional | 1 | 2010 | 136 | 0.090 |
Why?
| Mice | 4 | 2016 | 5739 | 0.080 |
Why?
| Tooth Extraction | 1 | 2009 | 8 | 0.080 |
Why?
| Gene Silencing | 1 | 2009 | 119 | 0.080 |
Why?
| Graft Rejection | 1 | 2010 | 161 | 0.080 |
Why?
| Immunohistochemistry | 2 | 2009 | 973 | 0.080 |
Why?
| Blood Loss, Surgical | 1 | 2009 | 72 | 0.080 |
Why?
| Drug Resistance, Neoplasm | 1 | 2010 | 308 | 0.080 |
Why?
| Paraffin Embedding | 1 | 2008 | 53 | 0.080 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 197 | 0.080 |
Why?
| Bone Wires | 1 | 2008 | 4 | 0.080 |
Why?
| Arteriovenous Malformations | 1 | 2009 | 67 | 0.080 |
Why?
| Mice, Inbred C57BL | 2 | 2010 | 1816 | 0.080 |
Why?
| Quinones | 1 | 2007 | 8 | 0.080 |
Why?
| Photomicrography | 1 | 2007 | 7 | 0.070 |
Why?
| Dental Occlusion | 1 | 2007 | 2 | 0.070 |
Why?
| Mandibular Neoplasms | 1 | 2007 | 6 | 0.070 |
Why?
| Carcinoma, Adenoid Cystic | 1 | 2007 | 5 | 0.070 |
Why?
| Predictive Value of Tests | 1 | 2010 | 903 | 0.070 |
Why?
| Jaw Diseases | 1 | 2007 | 6 | 0.070 |
Why?
| Skull Base Neoplasms | 1 | 2007 | 21 | 0.070 |
Why?
| Ear Cartilage | 1 | 2007 | 5 | 0.070 |
Why?
| Osteotomy | 1 | 2007 | 32 | 0.070 |
Why?
| Bone Transplantation | 1 | 2007 | 47 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 595 | 0.070 |
Why?
| Macrophages | 1 | 2009 | 363 | 0.070 |
Why?
| Osteonecrosis | 1 | 2007 | 34 | 0.070 |
Why?
| MicroRNAs | 1 | 2010 | 353 | 0.070 |
Why?
| Salvage Therapy | 2 | 2022 | 139 | 0.070 |
Why?
| Sesquiterpenes | 1 | 2007 | 90 | 0.070 |
Why?
| Blood Vessels | 1 | 2007 | 72 | 0.070 |
Why?
| Equipment Design | 1 | 2007 | 284 | 0.070 |
Why?
| Logistic Models | 1 | 2009 | 888 | 0.070 |
Why?
| Bone Density Conservation Agents | 1 | 2007 | 77 | 0.070 |
Why?
| Diphosphonates | 1 | 2007 | 90 | 0.070 |
Why?
| Swine | 1 | 2007 | 393 | 0.070 |
Why?
| Analysis of Variance | 1 | 2007 | 562 | 0.070 |
Why?
| Severity of Illness Index | 1 | 2009 | 945 | 0.070 |
Why?
| Transplantation, Heterologous | 1 | 2006 | 74 | 0.070 |
Why?
| Models, Theoretical | 1 | 2007 | 175 | 0.070 |
Why?
| Azepines | 2 | 2016 | 18 | 0.070 |
Why?
| Pilot Projects | 2 | 2022 | 699 | 0.070 |
Why?
| Image Processing, Computer-Assisted | 1 | 2007 | 242 | 0.070 |
Why?
| Microsurgery | 2 | 2021 | 29 | 0.070 |
Why?
| Stress, Mechanical | 1 | 2006 | 88 | 0.060 |
Why?
| Hypoglossal Nerve | 1 | 2005 | 4 | 0.060 |
Why?
| Carotid Arteries | 1 | 2005 | 85 | 0.060 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2016 | 211 | 0.060 |
Why?
| Disease Models, Animal | 1 | 2010 | 1455 | 0.060 |
Why?
| Neoplasm Staging | 1 | 2007 | 740 | 0.060 |
Why?
| Triazoles | 2 | 2016 | 108 | 0.060 |
Why?
| Fracture Healing | 1 | 2004 | 27 | 0.060 |
Why?
| Range of Motion, Articular | 1 | 2004 | 108 | 0.060 |
Why?
| Fibula | 1 | 2023 | 21 | 0.060 |
Why?
| Endoscopy | 1 | 2004 | 124 | 0.060 |
Why?
| Risk Factors | 1 | 2012 | 3613 | 0.060 |
Why?
| Forearm | 1 | 2023 | 31 | 0.060 |
Why?
| Vascular Surgical Procedures | 1 | 2005 | 165 | 0.050 |
Why?
| Ibuprofen | 1 | 2022 | 21 | 0.050 |
Why?
| Ambulatory Care Facilities | 1 | 2023 | 125 | 0.050 |
Why?
| Tumor Cells, Cultured | 2 | 2016 | 465 | 0.050 |
Why?
| Ambulatory Care | 1 | 2023 | 222 | 0.050 |
Why?
| Anastomosis, Surgical | 1 | 2021 | 66 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2021 | 206 | 0.050 |
Why?
| Neoplasms, Squamous Cell | 2 | 2011 | 7 | 0.050 |
Why?
| Drug Administration Schedule | 1 | 2021 | 376 | 0.050 |
Why?
| Promoter Regions, Genetic | 2 | 2015 | 475 | 0.040 |
Why?
| Odds Ratio | 1 | 2021 | 545 | 0.040 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1537 | 0.040 |
Why?
| Child, Preschool | 1 | 2008 | 3871 | 0.040 |
Why?
| Reproducibility of Results | 1 | 2023 | 1193 | 0.040 |
Why?
| Pain Management | 1 | 2021 | 160 | 0.040 |
Why?
| Child | 2 | 2009 | 6847 | 0.040 |
Why?
| Cell Line, Tumor | 2 | 2015 | 1403 | 0.040 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 989 | 0.040 |
Why?
| Patient Readmission | 1 | 2019 | 219 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 861 | 0.040 |
Why?
| Patient Discharge | 1 | 2019 | 320 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2016 | 96 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2016 | 143 | 0.030 |
Why?
| Drug Synergism | 1 | 2016 | 150 | 0.030 |
Why?
| Mice, SCID | 1 | 2016 | 175 | 0.030 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 17 | 0.030 |
Why?
| Infant | 1 | 2024 | 3567 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.030 |
Why?
| Acetylation | 1 | 2015 | 97 | 0.030 |
Why?
| Enhancer Elements, Genetic | 1 | 2015 | 61 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 377 | 0.030 |
Why?
| Blotting, Western | 1 | 2016 | 601 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2015 | 231 | 0.030 |
Why?
| Chromatin | 1 | 2015 | 151 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2015 | 166 | 0.030 |
Why?
| Protein Binding | 1 | 2015 | 660 | 0.030 |
Why?
| RNA, Messenger | 1 | 2016 | 1105 | 0.030 |
Why?
| Administration, Topical | 1 | 2011 | 56 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2010 | 52 | 0.020 |
Why?
| Deferoxamine | 1 | 2009 | 9 | 0.020 |
Why?
| Treatment Failure | 1 | 2010 | 114 | 0.020 |
Why?
| Biopsy | 1 | 2011 | 584 | 0.020 |
Why?
| Drug Combinations | 1 | 2009 | 123 | 0.020 |
Why?
| Lymphatic Metastasis | 1 | 2010 | 224 | 0.020 |
Why?
| Keratinocytes | 1 | 2009 | 90 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2009 | 75 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2009 | 192 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2009 | 453 | 0.020 |
Why?
| Flow Cytometry | 1 | 2011 | 476 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1376 | 0.020 |
Why?
| Nitric Oxide | 1 | 2009 | 253 | 0.020 |
Why?
| Cranial Nerve Neoplasms | 1 | 2007 | 6 | 0.020 |
Why?
| False Negative Reactions | 1 | 2007 | 30 | 0.020 |
Why?
| Radiographic Image Enhancement | 1 | 2007 | 30 | 0.020 |
Why?
| False Positive Reactions | 1 | 2007 | 63 | 0.020 |
Why?
| Curettage | 1 | 2007 | 13 | 0.020 |
Why?
| Dental Care | 1 | 2007 | 11 | 0.020 |
Why?
| Skin Temperature | 1 | 2007 | 15 | 0.020 |
Why?
| Image Enhancement | 1 | 2007 | 54 | 0.020 |
Why?
| Hyperbaric Oxygenation | 1 | 2007 | 14 | 0.020 |
Why?
| Survival Rate | 1 | 2009 | 894 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2007 | 94 | 0.020 |
Why?
| Imidazoles | 1 | 2007 | 119 | 0.020 |
Why?
| Hot Temperature | 1 | 2007 | 207 | 0.020 |
Why?
| Cells, Cultured | 1 | 2009 | 1573 | 0.020 |
Why?
| Contrast Media | 1 | 2007 | 184 | 0.020 |
Why?
| DNA Methylation | 1 | 2009 | 548 | 0.020 |
Why?
| Cadaver | 1 | 2005 | 97 | 0.020 |
Why?
| Fluorouracil | 1 | 2004 | 54 | 0.010 |
Why?
| Lymph Node Excision | 1 | 2004 | 134 | 0.010 |
Why?
| Cisplatin | 1 | 2004 | 278 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 2010 | 1171 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2004 | 637 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2007 | 744 | 0.010 |
Why?
| Young Adult | 1 | 2009 | 3958 | 0.010 |
Why?
| Cross-Sectional Studies | 1 | 2004 | 1557 | 0.010 |
Why?
| Multiple Myeloma | 1 | 2007 | 2929 | 0.010 |
Why?
|
|
Vural's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|